FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology, in particular, to modification of proteins, and describes a method for regioselective chemical N-terminal gexa-ilirovation of thymosin beta 4, as well as monoconjugate produced as described above. Method is characterized by that is anhydride of hexanic acid is dissolved in multicomponent aqueous-organic buffer with pH 3, providing regioselective gexa-ilirovating and containing desacetilthymosin beta 4, incubated for 3 hours at 25 °C, cleaned by method OF VEJH and is lyophilized. Monoconjugat of hexanoic acid with thymosin beta 4 has improved pharmacokinetic properties.
EFFECT: invention enables to obtain monogexailirovaned thymosin beta 4 with high output and can be used in medicine and pharmaceutical industry.
2 cl, 4 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COVALENT MONOCONJUGATE OF POLYETHYLENE GLYCOL WITH THYMOSIN BETA 4, RESISTANT TO DEGRADATION IN BLOODSTREAM AND METHOD FOR ITS PRODUCTION | 2015 |
|
RU2607527C2 |
| METHOD OF PRODUCING MONO CONJUGATE OF POLYSIALIC ACID WITH THYMOSIN BETA 4 AND COVALENT MONO CONJUGATE OF POLYSIALIC ACID WITH THYMOSIN BETA 4, RESISTANT TO DEGRADATION IN A BLOOD FLOW | 2015 |
|
RU2605385C2 |
| NEW FUNCTIONAL, HIGH-PURITY STABLE CONJUGATE OF GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND POLYETHYLENE GLYCOL WITH PROLONGED BIOLOGICAL ACTION, APPLICABLE FOR MEDICAL PURPOSES, AND BASED IMMUNOBIOLOGICAL AGENT | 2010 |
|
RU2446173C1 |
| PEG-MODIFIED HUMAN INTERFERON β-1a MOLECULE WITH ANTIVIRAL, IMMUNOMODULATORY AND ANTIPROLIFERATIVE ACTIVITY, WITH IMPROVED STABILITY, REDUCED IMMUNOGENICITY, IMPROVED PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS, SUITABLE FOR MEDICAL USE, AND IMMUNOBIOLOGICAL FORMULATION BASED THEREON | 2013 |
|
RU2576372C2 |
| DERIVATIVE OF INSULINOTROPIC PEPTIDE THAT CONTAINS MODIFIED N-ENDED AMINOACID | 2008 |
|
RU2442792C2 |
| ANTIBIOTIC PEPTIDES | 2008 |
|
RU2472805C2 |
| INSULINOTROPIC COMPLEX IN WHICH IMMUNOGLOBULIN FRAGMENT IS USED | 2008 |
|
RU2436589C2 |
| PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATMENT OF GROWTH HORMONE-RELATED DISEASES IN HUMANS | 2019 |
|
RU2802215C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING GROWTH HORMONE-ASSOCIATED DISEASES IN HUMANS | 2014 |
|
RU2689336C2 |
| PEGYLATED COMPOUNDS OF RECOMBINANT HUMAN GROWTH HORMONE | 2009 |
|
RU2530714C9 |
